Bank of America has increased its price target for AptarGroup's stock, citing the company's strong performance in the injectables segment. This adjustment reflects the bank's confidence in AptarGroup's ability to capitalize on the growing demand for injectable pharmaceutical products. The revised target indicates a positive outlook for the company's financial prospects in this sector.
Related Articles
Don't miss out on breaking stories and in-depth articles.